Victory Capital Management Inc. purchased a new stake in Bioventus Inc. (NYSE:BVS – Get Rating) during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 23,208 shares of the company's stock, valued at approximately $279,000.

A number of other hedge funds have also bought and sold shares of BVS. Nuance Investments LLC grew its position in shares of Bioventus by 10.7% during the 4th quarter. Nuance Investments LLC now owns 1,275,040 shares of the company's stock worth $18,475,000 after purchasing an additional 123,283 shares in the last quarter. Tamarack Advisers LP raised its holdings in Bioventus by 82.3% in the 4th quarter. Tamarack Advisers LP now owns 875,000 shares of the company's stock valued at $12,679,000 after acquiring an additional 395,000 shares in the last quarter. Rice Hall James & Associates LLC lifted its position in shares of Bioventus by 44.6% during the 4th quarter. Rice Hall James & Associates LLC now owns 536,098 shares of the company's stock valued at $7,768,000 after acquiring an additional 165,269 shares during the period. Soleus Capital Management L.P. lifted its position in shares of Bioventus by 352.8% during the 4th quarter. Soleus Capital Management L.P. now owns 428,397 shares of the company's stock valued at $6,207,000 after acquiring an additional 333,795 shares during the period. Finally, Northern Trust Corp grew its holdings in shares of Bioventus by 89.0% during the 4th quarter. Northern Trust Corp now owns 258,899 shares of the company's stock worth $3,752,000 after purchasing an additional 121,887 shares in the last quarter. 86.85% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, Morgan Stanley boosted their price target on Bioventus from $11.00 to $12.00 and gave the company an "overweight" rating in a research note on Friday, August 12th.

Bioventus Stock Down 2.8 %

Bioventus (NYSE:BVS – Get Rating) last posted its quarterly earnings results on Thursday, August 11th. The company reported $0.10 EPS for the quarter, missing analysts' consensus estimates of $0.14 by ($0.04). The business had revenue of $140.33 million for the quarter, compared to analyst estimates of $140.01 million. Bioventus had a positive return on equity of 10.35% and a negative net margin of 4.26%. During the same period last year, the firm posted $0.16 EPS. Research analysts forecast that Bioventus Inc. will post 0.54 EPS for the current fiscal year.

About Bioventus

(Get Rating)

Bioventus Inc a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products.

Read More

• Get a free copy of the StockNews.com research report on Bioventus (BVS)
• 2 EV Suppliers Powering To Gains After Raising Views
• Applied Materials Results Show A Slowing Semiconductor Market
• MarketBeat: Week in Review 8/15 – 8/19
• Near-Term Headwinds Present An Opportunity In Ross Stores
• Apple's Stock Could Be On The Verge Of Another 30% Rally

Want to see what other hedge funds are holding BVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bioventus Inc. (NYSE:BVS – Get Rating).

Receive News & Ratings for Bioventus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioventus and related companies with MarketBeat.com's FREE daily email newsletter.